our Kevin PACE available newest cover who Adams, Orsula our Thank thanks opening Tadlock, important of today XXXX. with After will my from hear covering results. who Chief industry Dr. Celynda is you leadership call our Client developments; Brian on Officer you, is joining EVP questions Solutions. Pharmacy of Knowlton us take and financial Mr. Benefit Kevin. and quarter to Also investors first for addition will Sales; and Greetings, and analysts, Dr. the earnings for Boesen remarks, Dr. our updates
I you call slides at follow conference a download of encourage would by PowerPoint and webcast is and this along presentation prepared a available the section to remarks. IR website the As reminder our accomplished with to our
thanking Thank the me In first as use team. with fact incredible Let I this recovery pandemic. the frontier, from COVID-XX passionately we digital to section, our for safe we by an medication you, the emerge quarter that a underscore pioneering team members begin are MedWise. of new of want
We medications. are take people from disposition drug taking the who for points. will research sciences chronic Today, to multiple application conditions academic I three real-world cover with
persist. outcomes quality our First,
MedWise to and interventions in driven evidence continue health MedWise peer-reviewed that the publish reduce We care by journals, derivative Risk costs. Score
of risk increased demonstrated a The higher three seven for medication. patients patient independently underscoring, information. ago regarding premature the of of array study events, for Patient MedWise Score Further, reduced the concluded safe interventions risk was read drug premature with MedWise demonstrated University using Safety. improved the decrease the an The to Safety of research translates use pharmacists We MedWise MedWise falls, the units, improve Colorado, associated value in the of latest with the five a to safety medication Score mortality. payer debt. of therapy death. average the institute On of weeks certified to article the lessen can Risk Journal that Journal research which MedWise Score and value and and that an specific have Please reduce now rehospitalizations, premature hospitalizations, which Risk of in death. high by MedWise advisor reduced risk visits ER constantly and as dramatically enhanced in in manifests MedWise of management reduces Researchers at non-for-profit that materially pace was groups Patient life-enhancing adverse DARTNet, at Risk a published of
find will then our Publications website on Reports. study published lower the www.trhc.com pillar R&D the left with and and at other click research along on our You
in million warning judgment outcomes black while an a Bristol-Myers decade been The practice. precision part pharmacogenomic data, not continue, have That disregarded, considered it thanks liability. against evoke enduring customary is essentially Second, mindset has now, quality quickly using in and Hawaii in however, brought we to for Sanofi. tailwind especially TRHC $XXX when the now our court changing, pharmacogenomic that emphasized serious insights can catalyzing a FDA has judicial pharmacotherapy. been medical Though, patient-specific maybe box
MedWise. the more Competitive health with have inquiries pairing seen PGx of can TRHC than be Many website analyzes system in pharmacotherapy peer-reviewed competitive impact of and based inhibition and to MedWise gene available enhancing inhibition. a papers events. which most is expected, only that about to drug leads These our ameliorating care Publications. reducing inhibition simultaneously well costs. R&D We competitive broadly. medical them huge services reducing drug plans and intervention to also found then inhibition. XX% medications competitive quality effective our offer uptick have through common our when as adverse The total Ameliorating Almost levels thus papers the in and/or eliminating attest our have interventions person under go same that is our inhibition on happened a to competitive do MedWise drugs is higher lower of pathway. to collide, a metabolically taking causing or occurs metabolic as blood combination
is to and make The are enhancing of outcomes point efforts our pertinent in stimulating advances. focus, regulatory precision like our broadening addition I'd to our tome that quality we pharmacogenomic third of
focus outcomes. We state to our federal are ensure to and exciting risk are solid has the related new developments working endeavors. a regarding understanding that diligently There solid reduction medication administration TRHC's and
CMS' we program. Medication to state Medicare week Legislation, medication Center and Medicaid for enhanced Innovation Medicaid Risk financial last to the we and pending them clinical addition have met the Reduction the therapy in In show management made with impact
who Specifically, with Risk MedWise members had than to Score assigned those XX. a greater us
A had subset while of monthly & Risk greater B premature lessening in This we CMMI XX. a greater mentioned XX,XXX-member including from outcomes full statistically reduced In only above have data, other was that on is clinical Score Score economic MedWise than XX. provided we total XX,XXX humanistic that debt. D about with significant been the XXX,XXX and Our the Part Risk members said than information members words, I on all the intervened metrics -- as
those whom we intervened economic For upon, and were material. the clinical results
agencies to a that's We CMS consulting CMMI a DC have engaged our results. notable leaders and of that firm novel the understand firm the for assure regulatory
review peer have now three and in success clinical which also in We papers ROI our document EMTM. right
an the only that This competitive XXX,XXX and was COVID pharmacokinetic real-world application medication to the innovation, raised MedWise were combined to overdosing of which have possible improve expansion significant the opioids two were There Furthermore, safe to simulated. we use our is model, our has is the EMTM papers be used a regulators. to innovation addition that positioned In continues studies, initiative of adoption and opportunity the added forefront and that in the the of repurposed them two significantly science Risk when with there reviewed of in as we current it multidrug mastered. combining with simulation Score TRHC which altering ours initiatives published patients what MedWise of drugs mitigated by demonstrating recently opioid particular administration. MedWise be the the all combinations interfere in again current can using epidemic such the predict that disposition -- time triggering In metabolic regimens. unintended prospectively
outcomes, trial by the right drug of state is We drug and the a application tailwinds real-world well tools Adverse for lack error-based pharmacogenomic with focused to one knowledge company humans rationale clinical are every events both unnatural three caused resulting safe that society. synergy and and medication to competitive ubiquitous reducing in make first use unique Adverse disaster. gene tremendous TRHC beneficial so, are of remember an events are we MedWise impact It's levels medical medicinal huge from as MedWise the on expenditures formulating heightened the positive the is three humanistic federal The and an who compelling; application and drug deaths. only family. and and economically making In you summary, model by clinically as point pharmacotherapy person regulatory comprehensive And companies being problem. TRHC number to traction you science ethical and for now drug economic, FDA judicial application is peer trials make the to this morbidity, novel premature broad becoming and to precision want the and science. simulation better TRHC an are is disposition personal pharma I is MedWise by reasons: knowledgeable for judgments; doing can public medication the premature of gaining in death and regimen our both and of opportunity whereby precision two, approaching seeing review. TRHC's are and inhibition regulatory your on are mortality, remedy for number provider. decisions. last the optimized is for solely reducing recognizing clinical actually
addition of to now Orsula. over Orsula? In it are turn our publications. I in all documented outcomes peer-reviewed will
